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Abstract
Amphiregulin (AR) and insulin-like growth factor-1 (IGF1) are growth factors known to promote non-small cell lung cancer (NSCLC)
survival. We have previously published that 1) AR and IGF1, secreted by H358 NSCLC cells, cooperate to protect those cells and H322
NSCLC cells from serum-starved apoptosis; 2) H358 cells resist to Bax-induced apoptosis through an inhibition of Bax conformational
change. We show here that the anti-apoptotic activity of AR/IGF1 combination is specifically abolished by the PKC inhibitors calphostin
C and staurosporine, but not by the MAPK and PI K inhibitors PD98059 and wortmannin, suggesting the involvement of a3
PKC-dependent, MAPK- and PI K-independent survival pathway. The PKC inhibitor rottlerin restores apoptosis induced by serum3
deprivation. In addition, phosphorylation of PKC and PKC/, but not of PKC/ , increases in serum-starved H358 cells and in H322 cellsII
treated with AR/IGF1 combination and is blocked by calphostin C. Combination of AR and IGF1 increases p90  and BadRsk
phosphorylation as well as it inhibits the conformational change of Bax by a PKC-dependent mechanism. Finally, PKC, PKC or p90Rsk
siRNAs block the anti-apoptotic activity of AR/IGF1 combination but have no effect on partial apoptosis inhibition observed with each
factor used alone. Constitutively active PKC expression inhibits serum deprivation-induced apoptosis, whereas a catalytically inactive
form of p90  restores it. Thus, AR and IGF1 cooperate to prevent apoptosis by activating a specific PKC-p90 -dependent pathway,Rsk Rsk
which leads to Bad and Bax inactivation. This signalling pathway is different to that used by single factor.
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In non small cell lung cancer (NSCLC), growth factors that bind to tyrosine kinase receptors, have been characterized for their ability to
inhibit apoptosis and promote cell survival through autocrine/paracrine loops ( ). They represent promising targets for new therapeutic1
strategies as illustrated by the clinical development of epidermal growth factor (EGF) receptor signaling pathway inhibitors and they might be
an alternative to conventional chemotherapy which fails to improve survival in most patients with NSCLC. A significant percentage of
tumorigenic human lung epithelial cells overexpress amphiregulin (AR) and EGF-related cytokines ( ) as well as members of the erbB receptor2
family, in particular the EGF receptor (erbB-1/HER1) that binds AR, and erbB-2/neu (HER2) ( , ). Such overexpression has been associated3 4
with shortened survival in patients with NSCLC ( ). Type 1 insulin like-growth factor (IGF1) receptor is also overexpressed in NSCLC ( );3–6 7
it is a major survival factor that protects cells from apoptosis induced by number of stimulus ( ), including serum withdrawal ( , ). Moreover,8 9 10
we have previously shown, on two NSCLC cell lines H322 and H358 that 1) H358 cells secrete AR and IGF1 that cooperate to inhibit
apoptosis induced by serum deprivation in an autocrine manner ( ). Those two factors also protect H322 cells from apoptosis in a paracrine11
manner when cells are incubated with conditioned medium from H358 cells (CM) or with the two growth factors at concentrations found in the
H358 CM ( ). 2) AR inhibits apoptosis through an IGF1-dependent survival pathway, independently of the EGF receptor ( ). 3) H358 cells11 11
resist to Bax-induced apoptosis through an inactivation of Bax conformational change ( ).12
The IGF1 receptor is known to exert its anti-apoptotic function mainly through activation of the phosphatidylinositol 3-kinase (PI K)/Akt3
pathway ( ) whereas the EGF receptor usually activates the Ras/Raf/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated13
kinase (ERK) pathway ( ) and the PI K pathway ( ). These two growth factor receptors signaling pathways promote NSCLC cells survival (14 3 15
, ) and converge with the cell death machinery to the phosphorylation and inactivation of Bad, a pro-apoptotic member of the Bcl2 family16 17
of proteins ( ). When phosphorylated on Ser  or Ser , Bad is complexed to the cytosolic 14.3.3 protein and fails to interact with the18–21 112 136
anti-apoptotic BclX  protein, thus favoring cell survival ( ). Phosphorylation of Bad on Ser  also directly suppresses its interaction withL 19 155
BclX  ( ). Akt, a kinase activated by growth factors though a PI K-dependent mechanism, phosphorylates Bad on Ser  ( , ).L 22 3 136 20 21
Furthermore, mitochondrial membrane-based protein kinase A (PKA) and protein kinase C (PKC) could also be implicated in Bad
phosphorylation. PKA is able to phosphorylate Bad on Ser  ( , , ) and Ser  ( ). Finally, the MAPK-activated p90 ribosomal S6 kinase112 19 23 24 155 22
(p90 ) phosphorylates Bad on Ser  ( , , ) in a PKC-dependent pathway ( , ).Rsk 112 19 23 24 25 26
The PKC family contains at least 12 isotypes classified into three groups according to their structure and cofactor requirement. In the first
group, conventional PKC (PKC , PKC , PKC  and PKC ) are diacylglycerol, calcium and phosphatidylserine-dependent. In the secondα βI βII γ
group, novel PKC (PKC , PKC , PKC , PKC  and PKC ) are diacylglycerol and phosphatidylserine-dependent but calcium-independent. Inδ ε η θ μ
the third group, atypical PKC (PKC , PKC  and PKC ) are activated only by phosphatidylserine ( , ). PKC-dependent signaling pathwaysζ ι λ 27 28
can promote cell survival. Overexpression of PKC , PKC  and PKC  increase the cells resistance to apoptosis and PKC inhibitors are knownα ε θ
to sensitize cells to death ( , , ). PKC  also interacts with the pro-apoptotic protein Bax and promotes survival of human prostate cancer26 29 30 ε
cells ( ).31
Based on our previous published results, the aim of the present study was first to characterize the molecular cascade activated by both
factors AR and IGF1, acting in cooperation, to protect NSCLC cells H322 and H358 from apoptosis induced by serum deprivation; secondly to
see whether or not this molecular cascade leads to Bax inactivation. We show here that combination of AR and IGF1 stimulates a PKC - andζ
PKC -dependent, MAPK- and PI K-independent, survival pathway. PKC inhibit serum deprivation-induced apoptosis through activation ofδ 3
p90  and inactivation of the pro-apoptotic molecules Bax and Bad. Finally, the pathways activated by AR or IGF1, used as single agent, areRsk
different from that observed, here, with the two factors used in combination.
EXPERIMENTAL PROCEDURES
Cell culture, serum withdrawal and H358 conditioned medium
The human H358 and H322 cells were cultured in RPMI 1640 medium (Gibco, Cergy Pontoise, France) with 10  heat-inactivated fetal%
calf serum. For serum deprivation, cells were rinsed twice in PBS and cultured in serum-free medium. After 8h, serum-free medium was
changed and cells cultured as described in each experimental condition. Conditioned medium (CM) from H358 cells was collected 72 h after
serum-free culture, centrifuged (5000g) at 4 C and stored at 80 C until use.° − °
We have previously shown that in H358 CM obtained from serum-free medium cell culture, IGF1 level was about 1 ng/ml, as usually
observed in CM of other analyzed cancer cell lines, but the AR level was very high: 5 ng/ml, 50 more than in CM from other analyzed cancer
cell lines ( ). In all experiments performed in this manuscript, levels of AR and IGF1 in H358 CM were controlled as described ( ) and11 11
shown to be similar.
Drug treatment ( )table 1
N , O -dibutyryladenosine 3 , 5 -cyclic monophosphate sodium salt (dbcAMP), bisindolylmaleimide I (GF109203X), PD98059 (Alexis6 2′ ′ ′
Biochemical, Laufelfingen, Switzerland), calphostin C, rottlerin, staurosporine and wortmannin (Sigma-Aldrich, Saint Quentin Fallavier,
France), Go6976, U0126, SB203580 and SB202190 (Calbiochem, VWR International S.A.S. France), were dissolved in DMSO; BAPTA/AM
(Alexis Biochemical) in acetonitrile; H89 (Sigma-Aldrich) in ethanol:H O (1:1); phorbol 12-myristate 13-acetate (PMA, Alexis Biochemical)2
in methanol. AR and IGF1 recombinant proteins (Sigma-Aldrich) were dissolved in fresh medium just before use. Cells were treated as
indicated in figures legends.
Transfections
Short interfering RNA (siRNA) targeting human PKC  ( ) and siRNA non specific control were synthesized by Eurogentec (Liege,δ 32
Belgium). Transfection of duplex siRNA was performed with oligofectamine  reagent (Invitrogen, Cergy Pontoise, France), following the™
manufacturer s instructions. Dharmacon siRNA SMARTpool PKC , Rsk1 and siRNA negative control were purchase from Upstate’ ζ
Biotechnology (Euromedex, Mundosheim, France). Transfection of siRNA SMARTpool was performed with siIMPORTER  reagent (Upstate™
Biotechnology), following the manufacturer s instructions. SiRNA were transfected into 60  confluent cells at the final concentration of 200’ %
nM. After 96 h or 120 h of transfection, the efficiency of knockdown was assessed by Western blotting.
Transient transfections were carried out using Fug ne 6 (Roche Diagnostics, Meylan, France) according to the manufacturer s protocol.è ’
H322 cells were transfected with 5 g of glutathione S-transferase-Bad (Cell Signaling Technology, Ozyme, St Quentin Yvelines) or pcDNAμ
empty vector. 24h after transfections, cells were exposed to the different effectors as indicated. H322 cells, cultured on Lab-Tek  two wells,®
were transfected with 2 g of PKC (constitutively active PKC  or PKC  isoforms ( )) or Rsk (Rsk2-KN) mutants or GFP-vector.μ ζ δ 33
Immunofluorescence was performed 96h after transfection.
Quantification of apoptotic cell death
Cells were incubated with the different effectors diluted in the medium for 96 h at the concentration indicated. The morphological changes
related to apoptosis were assessed by fluorescence microscopy after Hoechst 33342 (5 g/ml, Sigma-Aldrich) staining of cells and the percentμ
of apoptotic cells was scored after counting at least 500 cells. The proteolytic activation of pro-caspase-3 was evaluated by Western Blotting.
Analysis of protein expression by Western blotting
Cells were washed, incubated in lysis buffer (Tris-Hcl 62.5 mM pH 6.8, glycerol 10 , -mercaptoethanol 5 , SDS 2 , urea 6M,% β % %
bromophenol blue) and sonicated. Proteins were subjected to electrophoresis and transferred to polyvinylidene difluoride membrane (PVDF,
Millipore, Saint Quentin les Yvelines, France). Bad, P90 , p44/42 MAPK and PKC isoforms were detected with phospho-specific antibodiesRsk
(Cell Signaling Technology, 1:1000 1:3000) or with antibodies that recognizes Bad (Cell Signaling Technology, 1:1000), Rsk1/MAPKAP-K1a–
(Upstate Biotechnology, 1:1000), p44/42 MAPK (New England Biolabs, Ozyme, St Quentin Yvelines, 1:1000) or the different PKC isoforms
(Becton Dickinson Transduction Lab, Le Pont de Claix, France, 1:250 1:1000 and Tebu for PKC , Le Perray en Yvelines, France, 1:500)– ζ
regardless of the phosphorylation state. For immunoblotting of active caspase-3, cells were incubated in lysis buffer (Tris-Hcl 50 mM pH 7.4,
Nacl 150 mM, EDTA 1 mM, Nonidet P-40 0.5 , NaF 1 mM, Na VO  1 mM, phenylmethylsulfonyl fluoride (PMSF) 0.5 mM, leupeptin,% 3 4
aprotinin and pepstatin 10 g/ml each) for 30 min on ice. Protein content was assessed by the Bio-Rad D  Protein Assay kit (Bio-Rad Lab.,μ C
Ivry sur Seine, France) and 60 g of cell lysates were subjected to electrophoresis. Caspase-3 was detected with anti-human caspase-3 rabbitμ
polyclonal antibody (Pharmingen, Becton Dickinson, 1:1000). To ensure equal loading and transfer, membranes were also probed for actin
using anti-actin rabbit polyclonal antibody (Sigma-Aldrich, 1:1000) or for HSP70 using anti-HSP70 mouse monoclonal antibody (Affinity
BioReagents Inc, 1:5000). The immunoreactive proteins were visualized using horseradish peroxidase conjugated goat anti-mouse or
anti-rabbit antibodies and enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech, Orsay, France).
Immunofluorescence staining
Cells cultured on Lab-Tek  were transfected as indicated. 96h after transfection, cells were fixed in 20 C acetone for 5 min. After® − °
washes, non specific binding sites were saturated in PBS/BSA 2 /normal goat serum 10  and incubation with anti-PKC  (1/250, Becton% % δ
Dickinson Transduction Lab) or anti-PKC  (1/500, Tebu) or anti-Rsk1/MAPKAP-K1a (1/250, Upstate Biotechnology) was carried out for 2h atζ
room temperature in PBS/BSA 2 . After three washes, Alexa  488 goat anti-rabbit IgG (H L) conjugate (Interchim, Montlu on, France,% ™ + ç
1:500), was added and cells were further incubated for 30 min in dark. Cells were then washed, counterstained with Hoechst 33342 and
observed using an Olympus microscope.
Protein immunostaining by flow cytometry
Cells were fixed in paraformaldehyde 0.5  for 5 min at room temperature, washed and nonspecific binding sites were blocked with 2% %
BSA in PBS/saponin 0.1  for 30 min at room temperature. Cells were then incubated for 2 h at room temperature in the presence of an%
anti-Bax rabbit polyclonal antibody (Santa Cruz Biotechnology, Tebu, 1:100) raised against the peptide sequence amino acids of N terminus
Bax protein or rabbit irrelevant IgG (Pharmingen, Becton Dickinson), washed, incubated for 30 min with Alexa  488 goat anti-rabbit IgG (H™ +
L) conjugate (Interchim, 1:500), washed again and resuspended in PBS. All antibodies were diluted in PBS containing 0.1  saponin and 1% %
BSA. Analysis was performed on a FACScan flow cytometer (Becton Dickinson) using Cellquest software. Green fluorescence was detected at
488 nm.
RESULTS
We have previously demonstrated that H358 cells resisted to serum-deprivation apoptosis and that serum-free conditioned medium (CM)
from H358 cells protected H322 NSCLC cells from apoptosis, although they are normally sensitive to serum deprivation ( ). The11
anti-apoptotic activity of H358 CM was completely abolished by a pre-incubation with the anti-AR neutralizing antibody and to a lower extent
(about 50 ) by the anti-IGF1 antibody. In contrast, neutralization of other putative growth factors did not alter anti-apoptotic activity of H358%
CM ( ). In addition, AR and IGF1 recombinant proteins, used in combination at the concentrations detected in H358 CM, mimicked the11
anti-apoptotic activity of H358 CM, whereas AR or IGF1, used as a single agent, partially inhibited apoptosis ( ). We have taken advantage of11
H358 and H322 NSCLC cells properties to analyze here the apoptosis inhibition pathway promoted by AR and IGF1.
H358 CM and combination of AR and IGF1 inhibit apoptosis by a PKC-dependent, MAPK- and PI K-independent, survival pathway3
The PI K, MAPK as well as the PKC and PKA are the prevalent intracellular pathways transmitting receptor-mediated anti-apoptotic3
signals from the cell surface to the nucleus. In order to determine which of these pathways was responsible of the apoptosis inhibition, specific
inhibitors ( ) were added to H322 cells cultured in H358 CM (with characterized levels of AR and IGF1 as described in methods) or intable 1
presence of AR and IGF1 recombinant proteins at the same concentrations as in H358 CM ( ).figure 1
Incubation of serum-starved H322 cells in the presence of the p42/44 MAPK inhibitor PD98059 and the PI K inhibitor wortmannin3
enhanced their apoptosis but did not affect the protective effect of the H358 CM or of the combination of AR and IGF1 ( ).figure 1A, B, F
Similarly, the anti-apoptotic activity of the H358 CM did not change with U0126, another p42/44 MAPK inhibitor, SB202190 or SB203580,
two p38 MAPK inhibitors, and the PI K inhibitor LY294002 (data not shown). In contrast, low concentrations of calphostin C (200 nM) and3
staurosporine (10 nM), which both inhibit the PKC pathway, restored apoptosis of H322 cells cultured in H358 CM or in presence of AR and
IGF1, but did not modify the percentage of apoptosis induced by serum deprivation in H322 cells ( ). The PKA inhibitor H89figure 1C, D, F
also enhanced apoptosis of H322 cells cultured in serum-free condition and of H358 CM but without statistical significance ( ). Infigure 1E
addition, dibutyryl 3 , 5 -cyclic adenosine monophosphate (dbcAMP), which activates PKA, did not inhibit serum deprivation-induced′ ′
apoptosis ( ). PD98059 and wortmannin, but not calphostin C, blocked the partial anti-apoptotic activity of AR alone, used at the samefigure 1E
concentration as in H358 CM, whereas wortmannin, but not PD98059 or calphostin C, seemed prevent the partial inhibition of apoptosis
observed with single agent IGF1 ( ).figure 1F
Similar experiments performed on H358 cells also demonstrated that PKC inhibitors staurosporine and calphostin C sensitized H358 cells
to serum deprivation-induced apoptosis, while wortmannin and PD98059 had no significant effect ( ).figure 2
Taken together, these data suggested that combination of AR and IGF1 present in the H358 CM inhibited apoptosis through activation of a
PKC-dependent survival pathway in NSCLC cells but not p42/p44 and p38 MAPK nor PI K pathways. AR or IGF1 single agent did not3
activated such PKC-dependent survival pathway.
H358 CM and AR/IGF1 combination involve atypical PKC and novel PKC to inhibit apoptosis
Among the PKC family, several PKC isoforms could be involved. The specific classical PKC inhibitor Go6976, the calcium chelator
BAPTA-AM (data not shown) or the inhibitor of both classical and novel PKC basindolylmaleimide I (GF109203X) did not influence the
capacity of H358 CM to inhibit the apoptosis induced by serum deprivation in H322 cells ( ). The phorbol 12-myristate 13-acetatefigure 3A, C
(PMA), which activates PKC, mimicked the anti-apoptotic effect of H358 CM in serum-starved H322 cells and this effect was totally block by
GF109203X, demonstrating that GF109203X was active ( ). Surprisingly, 1 M of rottlerin, which inhibits novel PKC , restoredfigure 3D μ δ
apoptosis of H322 cells cultured in H358 CM ( ). Altogether, these data suggested that apoptosis inhibition involved the atypical PKCfigure 3B
and the novel PKC  but was independent of classical PKC and of the known anti-apoptotic effect of PMA.δ
In order to control that the PKC-dependent survival pathway was independent of the MAPK pathway, p42/p44 MAPK phosphorylation
status was examined in H358 and H322 cells using specific antibody recognizing Thr /Tyr  phosphorylated residues. As expected, in both202 204
cell lines, PD98059 incubation dramatically prevented p42/p44 phosphorylation ( ). In serum-starved H358 cells, p42/p44 MAPKfigure 3E
phosphorylation level did not change as compared to control culture condition. Similar levels of phosphorylated p42/p44 were also detected in
the presence of specific PKC inhibitors. In H322 cells, as compared to serum-starved condition, H358 CM enhanced the level of
phosphorylation of p42/p44 MAPK, but this effect was not abolished by specific inhibitors of PKC calphostin C, staurosporine or rottlerin (
). This suggested that the PKC-dependent anti-apoptotic pathway induced by H358 CM did not involve p42/p44 MAPK, even if thisfigure 3E
latter was activated by H358 CM.
H358 and H322 NSCLC cells expressed conventional PKC / , novel PKC , PKC  and PKC  and atypical PKC  and PKC / , but not PKCα β δ ε η ζ ι λ
 and PKC  ( ). To further investigate the putative involvement of atypical PKC and PKC , the phosphorylation status of PKCγ θ figure 4A δ
isoforms was analyzed in H358 and H322 cells in the presence of specific PKC inhibitors ( ). The robust basal phosphorylation offigure 4B
PKC /  Thr  remained unchanged whatever the stimulus applied to H358 or H322 cells. Serum-starvation of H358 cells and treatment ofα β2 638/641
H322 cells with H358 CM or with a combination of AR and IGF1 induced a strong phosphorylation of PKC  Thr  as compared to controlδ 505
culture condition. This activation was blocked by the use of PKC inhibitors calphostin C, staurosporine and rottlerin. Phosphorylation of PKCδ
Ser  was not detected (data not shown). The phosphorylation level of PKC /  Thr  increased in serum-starved H358 and H322 cells653 ζ λ 410/403
treated with H358 CM or with AR and IGF1 together, as compared to control culture condition and was inhibited by calphostin C and to a
lower level by staurosporine. The use of rottlerin did not have a significant effect on PKC /  phosphorylation. In addition, AR or IGF1 used asζ λ
single agent, did not induce the same phosphorylation of PKC  Thr  and PKC /  Thr  as the combination of AR and IGF1 or H358 CM (δ 505 ζ λ 410/403
).figure 4B
This suggested that the cooperation of AR and IGF1 in H358 CM, but not AR or IGF1 single factor, inhibited serum deprivation-mediated
apoptosis through PKC  and PKC /  activation.δ ζ λ
PKC-dependent survival pathway, activated by AR and IGF1, leads to p90  activation and Bad inactivationRsk
It has been shown that phorbol esters prevented apoptosis by activating a PKC- and p90 -dependent pathway, MAPK-independentRsk
pathway, that led to inactivation of Bad ( ). We thus analyzed the phosphorylation status of p90  and Bad in H322 cells.26 Rsk
H358 CM, as well as combination of AR and IGF1 recombinant proteins, in the same ratio as in H358 CM, induced a strong
phosphorylation of p90  Ser  and Thr  ( ). This was abolished by the specific PKC inhibitor calphostin C. This increase ofRsk 381 573 figure 5A
phosphorylation was not observed with AR or IGF1 alone. The basal phosphorylation of p90  Thr /Ser  remained unchanged in theRsk 359 363
presence of H358 CM with or without PKC inhibitor calphostin C and in presence of AR and IGF1 recombinant proteins together or alone.
Serum starvation decreased faintly the phosphorylation level of p90  Thr /Ser  as compared to control culture conditions ( ). ThisRsk 359 363 figure 5A
suggested that the basal phosphorylation of these residues was independent of H358 CM PKC-mediated survival pathway, even if it was
decreased by serum-deprivation.
Additionally, serum-starvation decreased Bad phosphorylation at Ser  and Ser  in H322 cells, whereas H358 CM or combination of AR112 155
and IGF1 recombinant proteins restored its phosphorylation ( ). AR or IGF1 alone did not restore the phosphorylation of Bad Ser  orfigure 5B 112
Ser . Calphostin C dramatically reduced H358 CM-mediated phosphorylation of Bad Ser , but not significantly of Ser . Phosphorylation155 112 155
of Bad Ser  was not detected (data not shown).136
Taken together, these results indicated that the combination of AR and IGF1, but not AR or IGF1 used alone, inhibited serum
deprivation-mediated apoptosis  a PKC-dependent pathway involving activation of p90  and inactivation of Bad through phosphorylation.via Rsk
PKC-dependent survival pathway, activated by AR and IGF1, prevents Bax conformational change
Previous studies have shown that the Bax protein changed of conformation and exposed its N terminus domain during apoptosis ( , , ).12 34 35
Using an epitope-specific antibody that only recognizes the N terminal extremity of Bax when it is exposed, we showed that serum deprivation
increased Bax conformational activation in H322 cells but not in H358 cells ( ). H358 CM or combination of AR and IGF1 recombinantfigure 6
proteins prevented Bax conformational-activation; the level of fluorescence, reflecting Bax conformational change, was similar in H322 cells
treated with H358 CM or with combination of AR and IGF1 and in untreated control cells ( ). AR or IGF1 used alone did not have thefigure 6B
same effect as the combination of the both growth factors. The presence of the specific PKC inhibitor calphostin C in H358 CM or in
serum-free medium supplemented with AR and IGF1, enhanced Bax activation and restored the level of Bax N terminus staining to the level of
serum-starved H322 cells. Similarly, calphostin C enhanced the staining of Bax N terminus in serum-starved H358 cells ( ).figure 6A
These observations highly suggested that inhibition of apoptosis by combination of AR and IGF1 came from the inhibition of Bax
conformational change by a PKC-dependent mechanism.
AR/IGF1 combination inhibits apoptosis through a PKC-, PKC- and p90 -dependent pathwayRsk
Taken together, our results suggested that H358 CM and combination of AR and IGF1 inhibited apoptosis-induced by serum deprivation
through a PKC- and p90 -dependent pathway. This pathway led to inactivation of Bad as well as conformational inactivation of Bax.Rsk
In order to confirm the involvement of PKC and p90 , we analyzed the effect of silencing subtype-specific PKC and p90  by siRNA inRsk Rsk
H322 cells ( ). Transfections of siRNA targeting PKC  or PKC  strongly silenced endogenous PKC  and PKC  respectively asfigure 7 δ ζ δ ζ
compared to transfections of non-specific siRNA. SiRNA for each PKC isoform did not inhibit the expression of the other isoform ( ).figure 7A
Transfection of siRNA targeting PKC  or PKC  totally restored apoptosis of H322 cells cultured in H358 CM or in presence of combination ofδ ζ
AR and IGF1 ( ). PKC  siRNA appeared to be more potent than PKC  siRNA. We also observed that the inhibition offigure 7B, C ζ δ
serum-starved H322 cells apoptosis by H358 CM or AR and IGF1 was blocked by the double transfection of siRNA targeting PKC  and PKCδ ζ
(data not shown). Moreover, the partial anti-apoptotic activity of AR or IGF1 used as single agent, was not prevented when PKC  or PKCδ ζ
were knocked-down ( ). Transfections of siRNA targeting p90  strongly silenced endogenous p90 , as compared to transfectionsfigure 7B C– Rsk Rsk
of non-specific siRNA ( ), and greatly increased apoptosis of cells cultured in presence of H358 CM or of combination of AR andfigure 7A
IGF1, but not in presence of AR or IGF1 alone ( ).figure 7D
Altogether, these data suggested that the inhibition of apoptosis by H358 CM or by the combination of AR and IGF1 involved both PKCζ
and PKC  as well as p90 , whereas single factor AR or IGF1 acted through different pathway.δ Rsk
In order to verify the activity of PKC and p90  on serum deprivation-mediated apoptosis, H322 cells were transiently transfected withRsk
mutant constructs and apoptosis of transfected cells, detected by immunofluorescence, was analyzed ( ). Overexpression offigure 8
constitutively active PKC  or PKC  isoforms strongly inhibited apoptosis of serum-starved H322 cells, as compared to GFP-transfected cells (ζ δ
). The double transfection of constitutively active PKC  and PKC  did not increase the inhibition of apoptosis. Moreover, introductionfigure 8 ζ δ
of a catalytically inactive form of Rsk, Rsk2-KN, strongly inhibited the protective effect of H358 CM. These results demonstrated that PKCζ
and PKC  isoforms and p90  protected cells from serum-deprivation-induced apoptosis.δ Rsk
DISCUSSION
In this manuscript, we have shown that, in two NSCLC cell lines H358 and H322, AR and IGF1 cooperate to prevent apoptosis induced by
serum deprivation by activating a PKC-dependent survival pathway different to that used by single factor AR or IGF1. Atypical PKC , novelζ
PKC  and p90  are the principal mediators in this signal transduction. This survival pathway leads ultimately to Bad as well as Baxδ Rsk
inactivation.
We have previously identified that AR and IGF1 are the key anti-apoptotic molecules in the conditioned medium from H358 cells and that
the cooperation of those growth factors inhibits apoptosis  both IGF1 and EGF receptors in NSCLC ( ). IGF1 receptor exerts itsvia 11
anti-apoptotic effect essentially through activation of the PI K pathway ( ), which promotes cell survival by phosphorylating Bad ( ). In3 13 18–21
agreement, the IGF1-mediated inhibition of apoptosis in our model of NSCLC cells seems prevented by PI K inhibitors ( ). However,3 figure 9A
alternative pathways have been proposed such as the MAPK pathway or the activation of Raf-1 and its translocation to the mitochondria ( ,36 37
). PKC are also involved in IGF1-dependent pathway activated during mitogenesis ( , ), cell migration ( ), proliferation ( ) or38 39 40–42 43
transformation ( , ). Moreover PKC  antisense oligonucleotide restores apoptosis, blocked by IGF1, in glioblastoma multiform cells ( ).41 44 α 45
EGF receptor activates both MAPK and PI K pathways ( , ). In agreement, we show that MAPK and PI K inhibitors block the3 14 15 3
AR-mediated inhibition of apoptosis ( ). To date, PKC pathway has not been described to directly propagate the EGF receptorfigure 9A
signaling. However, EGF receptor triggers PKC activity ( ) at least in part downstream of phospholipase signaling ( ) and EGF has recently46 47
been shown to induce fibroblast contractility and motility  a PKC -dependent pathway ( ). In our model of NSCLC cells, thevia δ 48
anti-apoptotic activity of H358 CM, mediated by AR/IGF1 cooperation, is prevented by PKC inhibitors but not by PI K or MAPK inhibitors,3
demonstrating the activation of an original PKC-dependent survival pathway ( ). Of note, although PKC might activate the MAPKfigure 9B
pathway ( , , , ), the phosphorylation of ERK1/2 proteins, by serum deprivation in H358 cells and by H358 CM in H322 cells, is25 26 49 50
independent of PKC; this result confirms that MAPK activation is not involved in the apoptosis inhibition mediated by combination of AR and
IGF1 in our model. Similarly, H89 restores apoptosis but the PKA activator dbcAMP has no significant protective effect, suggesting that the
PKA pathway is also not involved in cells survival.
Specific PKC isoforms may be either anti- or pro-apoptotic, depending on the nature of the apoptotic stimuli and of the cell type ( ).51
Known anti-apoptotic PKC isoforms include PKC , PKC , PKC , PKC /  and PKC  ( , , , ). Conversely, PKC  has been shown toα βII ε λ ι ζ 29 49 52 53 δ
have anti- or pro-apoptotic actions ( ). In our model, conventional PKC are not involved in apoptosis inhibition. Specific inhibitors of atypical54
PKC are not available, but the use of conventional and novel PKC inhibitors strongly suggests that the atypical PKC play a central role in the
survival pathway mediated by AR and IGF1. This hypothesis is confirmed by the inhibition of the AR/IGF1 survival pathway when we use
siRNA directed against atypical PKC . We also demonstrate that rottlerin and siRNA targeting novel PKC  restore apoptosis. PKC  and PKCζ δ ζ δ
are thus involved in the anti-apoptotic pathway activated by AR and IGF1. In addition, overexpression of constitutively active PKC  and PKCζ δ
strongly inhibits serum deprivation-induced apoptosis, suggesting that these PKC isoforms are sufficient for apoptosis inhibition. Our results
comfort previous data showing that PKC  plays an essential role in IGF1 regulation of cell proliferation, migration, gene expression ( ) andζ 41
mitogenesis ( , ). The major activation pathway of PKC  depends on PI K but it may also act independently of the PI K pathway ( ), in38 39 ζ 3 3 41
the MAPK cascade, the transcriptional factor NF B activation or Rsk signaling ( ). Our results are also in agreement with studies showingκ 50
that PKC  promotes cellular survival and chemotherapeutic drug resistance in NSCLC cells ( ) or is involved in IGF1 receptor-mediated cellδ 55
migration ( ) and transformation ( ).40 44
Caspases can cause limited proteolysis of PKC , generating a 40 kDa C-terminal fragment. It was proposed that the catalytic fragment ofδ
PKC  is pro-apoptotic and the holoenzyme is anti-apoptotic ( , ). In our model, we do not detect the 40 kDa fragment, except after PMAδ 54 56
treatment (data not shown). In addition, the novel PKC inhibitor GF109203X has no effect on the anti-apoptotic activity of H358 CM,
suggesting that the PKC -dependent pathway triggered by AR and IGF1 is independent of the anti-apoptotic activity of phorbol esters.δ
PKC  or PKC  siRNAs completely inhibit the survival pathway mediated by H358 CM or combination of AR and IGF1. In addition,ζ δ
transfection of siRNA targeting both PKC isoforms does not increase apoptosis restoration (data not shown), and the double transfection of
constitutively active PKC  and PKC  does not have additive effect on apoptosis inhibition. This confirmed that both PKC are on a uniqueζ δ
pathway. Moreover, rottlerin inhibits the phosphorylation of PKC  Thr  in serum-starved H358 cells and in H322 cells treated with H358δ 505
CM, but does not block the phosphorylation of PKC /  Thr  in the same conditions, indicating that the PKC  may act upstream the PKC  (ζ λ 410/403 ζ δ
). This is in agreement with previous observations showing that the function of PKC  may be influenced by the presence of otherfigure 9B δ
PKC isozymes ( ) and that PKC  could control PKC  phosphorylation ( ).54 ζ δ 57
We show here that calphostin C and PKC  or PKC  siRNA inhibit survival pathway activated by the combination of AR and IGF1 butζ δ
have no effect when each growth factor are used as a single agent. This PKC-dependent survival pathway, activated by the combination of AR
and IGF1, is different of the pathways activated by AR or IGF1 used as single agent. Each factor activates the classical ways described
respectively for the EGF and IGF1 receptors ( ). Altogether, our results suggested that the cooperation between AR and IGF1 takesfigure 9A
place upstream of the PKC cascade, probably at the level of receptors. In agreement with this hypothesis, we have previously identified that AR
inhibits apoptosis through an IGF1-dependent survival pathway in NSCLC ( ), but the mechanism responsible of such cooperation remains to11
be determined.
In our study, the PKC-survival pathway involves the activation of p90  and the phosphorylation of Bad on Ser  ( ). This isRsk 112 figure 9B
confirmed by AR/IGF1 survival pathway inhibition, when we use siRNA directed against p90 . We also demonstrate that overexpression of aRsk
catalytically inactive form of Rsk prevents the anti-apoptotic activity of H358 CM, demonstrating the major role of this protein in AR/IGF1
survival pathway. Accordingly, the MAPK-activated p90  has been reported to protect cells from Bad-induced apoptosis by phosphorylationRsk
of Bad on Ser  both  and  ( , ). Moreover, phorbol esters promote cell survival essentially through a PKC-p90 -dependent,112 in vitro in vivo 23 25 Rsk
MAPK-independent pathway that lead to phosphorylation and inactivation of Bad ( ). Of note, in our model, AR and IGF1 also enhance the26
phosphorylation of Bad on Ser  independently of the PKC, as it is not modify by calphostin C. Phosphorylation of Bad on Ser  might be155 155
mediated by PKA, as previously described ( ), since the PKA inhibitor H89 has a pro-apoptotic effect in our model. We do not detect any22
phosphorylation of Bad Ser  by AR and IGF1 (not shown), a result in agreement with an Akt-dependent phosphorylation of this residue ( ,136 20
). These observations confirm the non-involvement of the PKA and PI K in the survival pathway induced by AR and IGF1.21 3
Forced expression of PKC  in prostate cancer cells confers a significant resistance to phorbol esters, associated with an inhibition of Baxε
conformational rearrangements ( ). This study suggested that an association of PKC  with Bax might neutralize apoptotic signals propagated31 ε
through a mitochondrial death-signaling pathway. We previously showed that H358 NSCLC cells resist to Bax-mediated apoptosis, due to an
inhibition of Bax conformational change and of its translocation from the cytosol to the mitochondria ( ). Here, we show that Bax12
conformational change inhibition is due to AR/IGF1 cooperation and the activation of a PKC-dependent pathway ( ).figure 9B
In conclusion, it is well established that growth factors, in particular EGF-related peptides and IGF1 are involved in survival of malignant
human lung epithelial cells through activation of intracellular MAPK and/or PI K pathways. Our study has demonstrated for the first time that3
1) the two growth factors, AR and IGF1, cooperate to induce an original PKC -, PKC - and p90 -dependent survival pathway in NSCLCζ δ Rsk
cells, independently of other pathways classically described for these two growth factors alone. 2) The PKC-dependent pathway induced by
AR/IGF1 cooperation can modify Bad phosphorylation and inactivate Bax conformational change. We thus have identified a new survival
pathway mediated by AR/IGF1 cooperation that might contribute to lung tumor development and progression. Further studies on the relevance
of this pathway  on fresh tumor samples will allow development of new therapeutic strategies.in vivo
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Abbreviations
 AR: amphiregulin
 dbcAMP: dibutyryl 3 , 5 -cyclic adenosine monophosphate′ ′
 EGF: epidermal growth factor
 GFP: green fluorescent protein
 H358 CM: conditioned medium from H358 cells
 IGF1: type 1 insulin-like growth factor
 MAPK: mitogen-activated protein kinase
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Figure 1
Effect of transduction pathway inhibitors on apoptosis induced by serum deprivation in H322 cells
H322 cells were cultured in medium with 10  serum (10 ), serum-free medium (0 ), serum-free H358 CM (CM) or serum-free medium% % %
supplemented with AR 5 ng/ml (AR) or IGF1 1 ng/ml (IGF1) or with the both recombinant proteins (AR IGF1). The activity of indicated+
concentrations of PD98059 ( ), wortmannin ( ), calphostin C ( ), staurosporine ( ), H89 or dbcAMP ( ) was analyzed.  The activity ofA B C D E F:
PD98059 10 M (PD), wortmannin 200 nM (Wort) or calphostin C 200 nM (CalC) was analyzed. Apoptosis was analyzed after 96h by detectionμ
of the active caspase-3 by immunoblotting or after counting Hoechst stained cells. Percentages of apoptosis are expressed as the mean  SD of at±
least three independent experiments (A E:  p<0.0001, statistically less significant than 0 ;  p<0.001, statistically more significant than H358– *** % **
CM; F:  p<0.005,  p<0,05, statistically less significant than 0 ).** * %
Figure 2
Effect of transduction pathway inhibitors on apoptosis induced by serum deprivation in H358 cells
H358 cells were cultured in presence (10 ) or absence (0 ) of serum. The activity of indicated concentrations of staurosporine ( ), calphostin C (% % A
), PD98059 or wortmannin ( ) was analyzed. Apoptosis was analyzed after 96h after counting Hoechst stained cells. Percentages of apoptosisB C
are expressed as the mean  SD of three independent experiments (  p<0.0001, statistically more significant than 0 ).± *** %
Figure 3
PKC inhibited apoptosis induced by serum deprivation in NSCLC cell lines independently of MAPK pathway
 H322 cells were cultured in medium with 10  serum (10 ), serum-free medium (0 ) or H358 CM (CM). The activity of indicatedA D:– % % %
concentrations of Go6976 ( ), rottlerin ( ), GF109203X (  and ) and PMA ( ) was analyzed. Apoptosis was analyzed after 96h after countingA B C D D
Hoechst stained cells. Percentages of apoptosis are expressed as the mean  SD of at least three independent experiments. (  p<0.001, statistically± ***
less significant than 0 ).  Western-blotting analysis of p42/p44 phosphorylated on Thr /Tyr  in H358 and H322 cells. Cells were incubated% E: 202 204
in medium with (10 ) or without (0 ) serum or in H358 CM (CM) supplemented with calphostin C 200 nM (CalC), staurosporine 10 nM (Stsp),% %
rottlerin 1 M (Rot) or PD98059 10 M (PD) as indicated. P42/p44 was used as protein level control. Results are representative of threeμ μ
independent experiments.
Figure 4
Phosphorylation of PKC isoforms following serum deprivation in NSCLC cells
 H358 and H322 cells were incubated for 30 min in control culture conditions.  H358 and H322 cells were incubated for 30 min with mediumA: B:
containing 10  serum (10 ), serum-free medium (0 ) or H358 CM (CM), supplemented with calphostin C 200 nM (CalC), staurosporine 100% % %
nM (stsp), rottlerin 1 M (Rot), or serum-free medium supplemented with AR 5 ng/ml (AR), IGF1 1 ng/ml (IGF1) or a combination of the bothμ
recombinant proteins (AR IGF1) as indicated. Cells lysates were separated by electrophoresis. Proteins were then blotted on to PVDF membranes,+
which were incubated with anti-isoform-specific PKC ( ) or anti-phospho-specific PKC ( ) antibodies as indicated. Actin or HSP70 were used asA B
protein level loading control. Results are representative of three independent experiments.
Figure 5
PKC promoted inhibition of apoptosis induced by serum deprivation by phosphorylating p90  and BadRsk
 H322 cells were incubated for 30 min with medium containing 10  serum (10 ), serum-free medium (0 ) in presence or absence of AR 5A: % % %
ng/ml (AR), IGF1 1 ng/ml (IGF1) or the both recombinant proteins (AR IGF1), H358 CM (CM) in presence or absence of calphostin C 200 nM+
(CM CalC) as indicated. Immunoblotting was done with phospho-specific p90  Ser , Thr  and Thr /Ser  antibodies or with an antibody+ Rsk 381 573 359 363
that recognizes p90  regardless of its phosphorylation state.  H322 cells were transfected with a glutathione S-transferase-Bad mammalianRsk B:
expression vector ( Bad) or an empty vector (pcDNA). 48h after transfection, cells were treated for 30 min as indicated in A. Immunoblotting was+
done with phospho-specific Bad Ser , Ser  and Ser  antibodies or with an antibody that recognizes Bad regardless of its phosphorylation112 136 155
state. Actin was used as protein level loading control. Results are representative of four independent experiments.
Figure 6
PKC promoted inhibition of apoptosis induced by serum deprivation by inhibiting the conformational change of Bax
Flow cytometry analysis of conformational change of Bax in H358 and H322 cells. Bax immunostaining was performed using a
conformational-dependent anti-Bax antibody that recognizes Bax protein with an exposed N terminus. H358 cells ( ) and H322 cells ( ) wereA B
treated for 96h as indicated: with (10 ) or without (0 ) serum, with H358 CM (CM), and supplemented or not with calphostin C 200 nM (CalC),% %
IGF1 1 ng/ml (IGF1) or AR 5 ng/ml (AR) or a combination of both recombinant proteins (AR IGF1). Dotted histogram: histogram for irrelevant+
antibody, open histogram: histogram for untreated control cells, filled histogram: histogram for treated cells as indicated. Results shown are
representative of three independent experiments.
Figure 7
Subtype-specific PKC and p90  knockdown in H322 NSCLC cellsRsk
 Western-blotting analysis of PKC , PKC  or p90  in H322 cells non-transfected ( ) or transfected with siRNA targeting PKC  ( ), PKC  ( ),A: δ ζ Rsk − δ δ ζ ζ
p90  (Rsk) or non-specific siRNA control (C). The efficiency of siRNA was analyzed 96h after transfection. Actin was used as protein levelRsk
control.  H322 cells were cultured in medium with (10 ) or without serum (0 ), H358 CM (CM) or serum-free medium supplemented withB D:– % %
AR 5 ng/ml (AR) or IGF1 1 ng/ml (IGF1) or with the both recombinant proteins (AR IGF1) and transfected with siRNA targeting PKC  ( ),+ δ B
PKC  ( ), p90  ( ) or non-specific siRNA control. Apoptosis was analyzed 96h after transfection after counting Hoechst stained cells.ζ C Rsk D
Percentages of apoptosis are expressed as the mean  SD of at least three independent experiments (  p<0.03, statistically more significant than± *
H358 CM and AR IGF1).+
Figure 8
Overexpression of PKC or p90  mutants in H322 NSCLC cellsRsk
 H322 cells, cultured in serum-free medium (0 ) or H358 CM (CM), were transfected with either a vector encoding green fluorescent proteinA: %
(GFP) or with an expression vector encoding the constitutively active PKC  ( CA) or PKC  ( CA) mutants or the catalytically inactive form ofζ ζ δ δ
p90  (Rsk2-KN). 96h after transfection, the expression of GFP, PKC , PKC  or p90  in transfected cells was revealed by immunofluorescenceRsk ζ δ Rsk
and morphological aspect of Hoechst-stained cells was analyzed. Arrows indicated apoptotic nuclei.  Apoptosis of transfected cells, as describedB:
in A, was analyzed after counting Hoechst counterstained cells. Percentages of apoptosis are expressed as the mean  SD of three independent±
experiments.
Figure 9
Schematic diagram showing the intracellular pathways for IGF1, AR or combination of the both growth factors involved in serum
deprivation-induced apoptosis in NSCLC cell lines
 Signaling pathways activated by IGF1 or AR growth factors used as single agent. IGF1 activates the IGF1 receptor and the PI K/Akt pathway.A: 3
AR activates the EGF receptor which is linked to the MAPK/ERK and the PI K/Akt pathways. Both IGF1 and EGF receptors converge to the3
inactivation of the pro-apoptotic protein Bad.  Survival pathway activated by the cooperation of IGF1 and AR growth factors. AR and IGF1,B:
present in the H358 CM, activate both IGF1 and EGF receptors (box) ( ). This cooperation induces a PKC-dependent survival pathway,11
independent of MAPK/ERK and PI K/Akt pathways. This anti-apoptotic pathway leads to Bad phosphorylation on Ser  and inhibition of3 112
conformational change of the pro-apoptotic protein Bax. Inhibitors used are mentioned in blue.
Table 1
Specific pathway inhibitors and activators used
Pathways Inhibitors Concentrations
Mμ






PKA H89 10 20–
PKC Calphostin C 0.2 0.5–
Staurosporine 0.01
Classical PKC G 6976ö 5
BAPTA-AM Until 100
Classical and novel GF109203X 2 5–
Novel PKCδ Rottlerin 0.1 1–
Pathways Activators Concentrations
Mμ
PKA dbcAMP Until 500
PKC Classical and novel PMA 0.1
